RENE — ReNeuron Share Price
Last trade - 00:00- £1.93m
- -£2.80m
- £0.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.75 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.8 | ||
| Price to Tang. Book | 0.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -235.29% | ||
| Return on Equity | -106.77% | ||
| Operating Margin | -2466.27% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.05 | 6.07 | 0.26 | 0.4 | 0.53 | 0.65 | 12.11 | 65.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
Directors
- Iain Ross NEC
- Olav Hellebo CEO
- Catherine Isted CFO (46)
- Shaun Stapleton VPR
- Richard Beckman OTH
- Suzanne Hancock OTH
- Stefano Pluchino OTH
- Timothy Corn NED
- Mark Evans NED
- Michael Owen NID (70)
- Barbara Staehelin NID (58)
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- June 7th, 2005
- Public Since
- August 12th, 2005
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 57,173,760
- Address
- Pencoed Business Park, BRIDGEND, CF35 5HY
- Web
- https://www.reneuron.com/
- Phone
- +44 2038198400
- Auditors
- PricewaterhouseCoopers LLP
Latest News for RENE
Upcoming Events for RENE
Full Year 2024 ReNeuron Group PLC Earnings Release
ReNeuron Group PLC Annual Shareholders Meeting
Similar to RENE
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:18 UTC, shares in ReNeuron are trading at 3.38p. This share price information is delayed by 15 minutes.
Shares in ReNeuron last closed at 3.38p and the price had moved by -68.99% over the past 365 days. In terms of relative price strength the ReNeuron share price has underperformed the FTSE All Share Index by -68.98% over the past year.
The overall consensus recommendation for ReNeuron is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
ReNeuron does not currently pay a dividend.
ReNeuron does not currently pay a dividend.
ReNeuron does not currently pay a dividend.
To buy shares in ReNeuron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 3.38p, shares in ReNeuron had a market capitalisation of £1.93m.
Here are the trading details for ReNeuron:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: RENE
Based on an overall assessment of its quality, value and momentum ReNeuron is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ReNeuron is 2.85p. That is 15.56% below the last closing price of 3.38p.
Analysts covering ReNeuron currently have a consensus Earnings Per Share (EPS) forecast of £0.00 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ReNeuron. Over the past six months, its share price has underperformed the FTSE All Share Index by -68.05%.
As of the last closing price of 3.38p, shares in ReNeuron were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ReNeuron PE ratio based on its reported earnings over the past 12 months is 18.75. The shares last closed at 3.38p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ReNeuron's management team is headed by:
- Iain Ross - NEC
- Olav Hellebo - CEO
- Catherine Isted - CFO
- Shaun Stapleton - VPR
- Richard Beckman - OTH
- Suzanne Hancock - OTH
- Stefano Pluchino - OTH
- Timothy Corn - NED
- Mark Evans - NED
- Michael Owen - NID
- Barbara Staehelin - NID